- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Citius Pharmaceuticals Inc (CTXR)
Citius Pharmaceuticals Inc stock price live, this page displays NASDAQ CTXR stock exchange data. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below.
What Is the Citius Pharmaceuticals Inc Stock Price Today?
The Citius Pharmaceuticals Inc stock price today is 0.570.
What Is the Stock Symbol for Citius Pharmaceuticals Inc?
The stock symbol for Citius Pharmaceuticals Inc is "CTXR."
What Stock Exchange Does Citius Pharmaceuticals Inc Trade On?
Citius Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Citius Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Citius Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. (ISIN: US17322U3068)
What Is the Citius Pharmaceuticals Inc Stock Price Today?
The Citius Pharmaceuticals Inc stock price today is 0.570.
What Is the Stock Symbol for Citius Pharmaceuticals Inc?
The stock symbol for Citius Pharmaceuticals Inc is "CTXR."
What Stock Exchange Does Citius Pharmaceuticals Inc Trade On?
Citius Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Citius Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Citius Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. (ISIN: US17322U3068)
0.570
-0.009(-1.49%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.570
0.570
52 wk Range
0.469
2.190
CTXR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5700.570
52 wk Range
0.4692.190
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CTXR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
4.000
Upside
+601.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.000
(+601.75% Upside)
Earnings
Latest Release
Aug 17, 2026
EPS / Forecast
-0.34 / 0.03
Revenue / Forecast
1.5M / 12.52M
Compare CTXR to Peers and Sector
Metrics to compare | CTXR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTXRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | 4.8x | −0.4x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 0.2x | 0.7x | 2.6x | |
Price / LTM Sales | 2.2x | 2.5x | 3.1x | |
Upside (Analyst Target) | - | 55.6% | 57.4% | |
Fair Value Upside | Unlock | 11.2% | 7.7% | Unlock |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Citius Pharma (CTXR) Stock Price Today?
The Citius Pharma stock price today is 0.570 USD.
What Stock Exchange Does Citius Pharma Trade On?
Citius Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Citius Pharma?
The stock symbol for Citius Pharma is "CTXR."
What Is the Citius Pharma Market Cap?
As of today, Citius Pharma market cap is 15.880M USD.
What Is Citius Pharma's Earnings Per Share (TTM)?
The Citius Pharma EPS (TTM) is -2.122.
When Is the Next Citius Pharma Earnings Date?
Citius Pharma will release its next earnings report on Dec 17, 2026.
From a Technical Analysis Perspective, Is CTXR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Citius Pharma Stock Split?
Citius Pharma has split 3 times.
How Many Employees Does Citius Pharma Have?
Citius Pharma has 23 employees.
What is the current trading status of Citius Pharma (CTXR)?
As of Sep 28, 2026, Citius Pharma (CTXR) is trading at a price of 0.570 USD, with a previous close of 0.579 USD. The stock has fluctuated within a day range of 0.570 USD to 0.570 USD, while its 52-week range spans from 0.469 USD to 2.190 USD.
What Is Citius Pharma (CTXR) Price Target According to Analysts?
The average 12-month price target for Citius Pharma is 4.000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +601.75% Upside potential.
What Is the CTXR Premarket Price?
CTXR's last pre-market stock price is 0.581 USD. The pre-market share volume is 330.000, and the stock has decreased by 0.002, or 0.350%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.